Bastian Dehmel
Corporate Officer/Principal bei OCULIS HOLDING AG
Profil
Bastian Dehmel is currently the Chief Development Officer at Oculis Holding AG.
Previously, he held the position of Executive Director-Global Medical Development at Amgen (Europe) GmbH from 2013 to 2017 and Chief Medical Officer at OxThera AB from 2017 to 2021.
Dr. Dehmel obtained a doctorate degree from Freie Universität Berlin.
Aktive Positionen von Bastian Dehmel
Unternehmen | Position | Beginn |
---|---|---|
OCULIS HOLDING AG | Corporate Officer/Principal | 01.01.2022 |
Ehemalige bekannte Positionen von Bastian Dehmel
Unternehmen | Position | Ende |
---|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2021 |
Amgen (Europe) GmbH | Corporate Officer/Principal | 01.07.2017 |
Ausbildung von Bastian Dehmel
Freie Universität Berlin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
OCULIS HOLDING AG | Health Technology |
Private Unternehmen | 2 |
---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
Amgen (Europe) GmbH |